Skip navigation
AI Applications Summit header

Healthcare &9642; Pharma &9642; Biotech

Download Brochure

December 11-12, 2017
Cambridge, MA

December 11-12, 2017 Royal Sonesta Boston Cambridge, MA

Real-Time Benefit Check & ePrior Authorization Summit banner ad
Medicaid and Government Pricing Congress banner ad
Pharmaceutical Compliance Congress Canada banner ad
Transparency and Aggregate Spend 2018 banner ad
IVT’s Cleaning Validation banner ad

Advisors & Speakers | AI Application Summit

Advisors & Speakers

Sameer Badlani headshot Sameer Badlani, MD, FACP
VP/Chief Health Information Officer
Sutter Health
Sameer Badlani headshot Sameer Badlani, MD, FACP, is the Vice President & Chief Health Information Officer for Sutter Health. Current areas of accountability include enterprise analytics, data management and clinical informatics. His areas of focus include using technology for clinician engagement, social psychology in the delivery of healthcare, and generating actionable analytics in clinical and business processes with the aim to automate workflows.

Dr. Badlani speaks nationally, as well as educates and consults on topics in clinical informatics, analytics, and quality and innovation in healthcare. As an experienced leader in healthcare IT, he advises venture capital funds and startups. In 2013 Dr. Badlani was recognized in Crain's Chicago 2013 “40 under 40” and nominated to the board of AMDIS, the premier international organization of CMIOs and executive physician leaders in informatics.

Board certified internist with expertise in inpatient transplant and consultative medicine, Dr. Badlani received his medical degree from the University of Delhi in India. After he completed his internal medicine residency training, Dr. Badlani served as chief resident at the University of Oklahoma in Tulsa. He received training in bio-medical informatics at the University of Utah in Salt Lake City.

Prior to joining Sutter Health, Dr. Badlani was the CHIO at Intermountain Healthcare, and before then, the CMIO and faculty at the University of Chicago Medicine and Biological Sciences.
John M. Baldoni headshot John M. Baldoni, Ph.D.
SVP, InSilico Discovery Performance
GSK Pharmaceuticals
John M. Baldoni headshot John Baldoni is Senior Vice President, In silico Drug Discovery, in GSK Pharma R&D. This department will use in silico methods to identify patient needs, explore molecular interventions to address those needs and design and conduct clinical trials to test the medical hypothesis. Using these methodologies, the conventional empirical design make test cycle will be dramatically reduced. The intent is to discover medicines at higher velocity, with greater precision and at dramatically lower cost compared to current approaches.

Prior to this, John was Senior Vice President, Platform Technology and Science (PTS), in GSK. The work of PTS span the entire drug discovery and development process, from preclinical activities leading to clinical candidate selection through commercial launch. This accountability covered the discovery and manufacture of small molecules, biopharmaceuticals, and cell and gene therapies.

John joined GSK in 1989 and has worked in the pharmaceutical industry for 37 years. His experience spans new chemical entity design, development and commercialization, and biopharmaceutical development. In progressing to his current role, John has held various positions at GSK including Senior Vice President, Preclinical Development; Vice President, Product Development; Director, Product Development; and Assistant Director, Biopharmaceutical Formulation Development, among others. He has led several key cross-functional strategic initiatives, such as advanced manufacturing technologies and discovery modernization.

John has a BS in biochemistry (1974), and MS and PhD degrees in chemistry (1980) from Penn State University.
Michael S. Blum headshot Michael S. Blum, MD FACC
Associate Vice Chancellor for Informatics, Chief Digital Technology Officer,
Director, Center for Digital Health Innovation;
Professor of Medicine, Cardiology, University of California, San Francisco**
Michael S. Blum headshot Dr. Michael Blum is the Associate Vice Chancellor for Informatics and a Professor of Medicine in Cardiology at UCSF. As an active clinician, Dr. Blum is passionate about wellness and prevention of heart disease through heart healthy lifestyle.

Prior to his medical career, Dr. Blum was trained as an engineer, and he applies his expertise in technology to health care as UCSF’s Chief digital Transformation Officer and the Director of the UCSF Center for Digital Health Innovation (CDHI). CDHI develops, validates, and commercializes novel, impactful digital health apps, devices, sensors, and platforms in pursuit of Precision Medicine. Dr. Blum serves as an advisor to numerous start-ups and early stage companies. CDHI has developed collaborations with major technology partners such as Cisco, GE Healthcare, Intel, Salesforce, and Samsung to develop and validate a variety of clinically impactful platforms, algorithms, and apps.

Previously, as UCSF’s Chief Medical Information officer, Dr. Blum led clinicians in the successful enterprise-wide deployment of Epic’s electronic health record as well as enterprise data warehousing. He is now focusing on implementation of next-generation patient-facing technologies that impact clinical quality, patient engagement, and cost as we work to transform healthcare delivery.
Cynthia Burghard headshot Cynthia Burghard
Research Director, Value-Based Healthcare IT Transformation Strategies
IDC Health Insights*
Cynthia Burghard headshot Cynthia Burghard is a Research Director with IDC Health Insights where she is responsible for research on Accountable Care.. Her passion is to provide the intelligence needed to manage the business and quality of healthcare. She has pioneered the use of healthcare information including building healthcare data warehouses at both the local and national level, developing and implementing analytics for employers, health insurance management, physicians, hospitals and government agencies.

As a highly sought-after industry analyst, Ms. Burghard is focused on qualitative and quantitative research on the involvement of consumers in healthcare decisions, best practices models for technology in care management and business intelligence, software vendor evaluation and future scenarios regarding the implications of technology in the healthcare industry. She has delivered the results of her research to all levels of management and healthcare sectors through the publication of over 100 research reports, articles and interviews, thought leadership papers and web seminars, presentations at national, regional and local venues, corporate marketing and sales training and through strategic consulting engagements.

As a Sr. Vice President for ikaSystems, a premier provider of enterprise-level cloud computing technologies for commercial, Medicare and Medicaid health plans, Ms. Burghard's work resulted in award-winning client case studies. At Gartner, she was responsible for directing all research for the healthcare payer market including healthcare business intelligence applications and healthcare payer market trends. She holds a Bachelor's degree from the University of Colorado.
Sandy Farmer headshot Sandy Farmer, Ph.D.
Executive Director, WRD Genome Sciences & Technologies
Pfizer Inc
Sandy Farmer headshot Since joining Pfizer in Dec. 2014, Dr. Sandy Farmer has held the position of Executive Director in the Dept. of Genome Sciences & Technologies in Worldwide R&D. His focus has been on formulating and advancing an R&D Data Strategy; on developing a systematic approach to Digital & Data Innovation for R&D in the Precision Medicine and AI strategic domains at the enterprise level; and on building out the cross-R&D data access and integration, technical infrastructure and AI / Machine Learning capabilities required to increase the impact of available genomic, phenotypic and exploratory clinical data on the Pfizer R&D portfolio. Prior to joining Pfizer, Dr. Farmer held the position of Global Head, Scientific Information Management Expert Center within the worldwide IT organization at Boehringer Ingelheim. In this role, he led a team of senior IT professionals responsible for developing and then advancing a global IT strategy around Scientific Information management. Dr. Farmer has been involved in Drug Discovery research for over 20 years, first with Bristol-Myers Squibb and then with Boehringer Ingelheim, and has co-authored over 60 scientific articles. He is a recognized Research leader and scientific expert in Structural Biology, Fragment-based Lead Discovery, and Small-Molecule Drug Design, and has extensive international experience in scouting out and integrating new computational and experimental technologies to advance drug discovery.
Arun Ghosh headshot

Arun Ghosh
Partner – Digital Enablement

Harry Glorikian headshot Harry Glorikian
General Partner, New Ventures Funds;
Author, MoneyBall Medicine: Thriving in the New Data-Driven Healthcare Market
Harry Glorikian headshot Harry Glorikian is an influential global business expert with more than three decades of experience building successful ventures in North America, Europe, Asia and the rest of the world. Harry is well known for achievements in life sciences, healthcare, diagnostics, healthcare IT and the convergence of these areas. He is a sought-after speaker, frequently quoted in the media, and regularly asked to assess, influence, and be part of innovative concepts and trends. He holds four US patents in telecommunications, and has others pending.

He currently serves as General Partner at New Ventures Funds. Before joining New Ventures Funds, he served as an Entrepreneur In Residence to GE Ventures – New Business Creation Group. He currently serves on the board of GeneNews Ltd. (a molecular diagnostic company). He also serves on the advisory board of Evidation Health (a digital health startup launched with support from GE Ventures), and several other companies. He is also a co-founder and an advisory board member of DrawBridge Health (a revolutionary diagnostics startup launched with support from GE Ventures).

Previously he co-founded and held the position of managing director and head of consulting services for Scientia Advisors, a company that became the go-to provider of strategic advice and implementation services for next-generation healthcare and life science innovators and Global 25 market leaders. Scientia Advisors was acquired by Precision for Medicine in November of 2012. Among his other professional roles, Mr. Glorikian served as senior manager for global business development at PE Applied Biosystems, founded X-Cell Laboratories, managed global sales at Signet Laboratories and held various roles at BioGenex Laboratories.

Mr. Glorikian holds an MBA from Boston University and a bachelor's degree from San Francisco State University. Harry has addressed the National Institutes of Health, Molecular Medicine Tri-Conference, World Theranostics Congress and other audiences, worldwide. He has authored numerous articles for industry publications, appeared on CBS Evening News and been quoted regularly by Dow Jones, The Boston Globe, BioWorld Today, Los Angeles Times, London Independent, Medical Device Daily, Science Magazine, Genetic Engineering News and many other media outlets. He is also the Author of two books: Commercializing Novel IVD’s; A Comprehensive Manual for Success and MoneyBall Medicine: Thriving in the New Data-Driven Healthcare Market.
Julie Locklear headshot Julie Locklear, PharmD, MBA
Independent Strategic Consultant; Former Vice President & Head, US Health Economics & Outcomes Research
EMD Serono, Inc., a business of Merck KGaA, Darmstadt, Germany**
Julie Locklear headshot Julie C. Locklear is Vice President & Head of Health Economics & Outcomes Research at EMD Serono, Inc., a business of Merck KGaA, Darmstadt, Germany.

“I am passionate about ensuring value considerations are in place early & often throughout the drug development process. Investment decision making & due diligence decisions must have patient-centric considerations & an end-to-end value evidence strategy to ensure products provide valuable differentiation for patients with difficult-to-treat diseases, leading to longer, healthier & more productive lives, while managing the cost impact to the healthcare system.”

As VP & Head of US HEOR at EMD Serono, Julie leads an in-house team specializing in strategic value proposition and end-to-end evidence generation, patient-centric real-world evidence, advanced analytics as well as a field HEOR team who interface with payers, IDNs, key opinion leaders and other access opinion leaders to provide evidence-based data across EMD Serono company products.

Julie is an executive pharmaceutical leader with over 20 years of experience across all phases of development, both on the commercial and research sides of pharmaceutical organizations. She leverages her Executive Masters in Business Administration and Doctorate in Pharmacy to lead a high functioning, high impact team delivering patient-centric value propositions to optimize patient access and improve outcomes in patients with difficult-to-treat diseases leading to longer, healthier and more productive lives. Her years of experience in global and US payer markets provide her with intimate knowledge of the current and evolving payer and market access landscapes in the US and around the globe. She has led the development and execution of several outcomes-based contracts with 3 of the largest national payer organizations in the US. Dr. Locklear is well published, having authored >30 peer-reviewed publications and >60 peer-reviewed abstracts presented at major scientific congresses.
Armaghan Naik headshot

Armaghan “Rumi” Naik, Ph.D.
Director and Head of Design Sciences, FluNeXt
Sanofi Pasteur

Eric Perakslis headshot Eric Perakslis, Ph.D.
Senior Vice President, Informatics Strategy and Professional Affairs
Takeda Pharmaceuticals
Eric Perakslis headshot Eric Perakslis is currently the Senior Vice President and Head of the Takeda R&D Data Science Institute where he is focused on building a next generation approach to biomedical knowledge infrastructure and culture. Eric is also a visiting Scientist in the Department of Biomedical Informatics ant Harvard Medical School and is a frequent advisor and collaborator to several international aid and relief NGOs.

Most recently, Eric was the Executive Director of the Center for Biomedical Informatics and the Countway Library of Medicine, an Instructor in Pediatrics at Harvard Medical School and is a faculty member of the Children’s Hospital Informatics Program at Boston Children’ Hospital.

Prior to HMS, Eric was the Chief Information Officer and Chief Scientist (Informatics) at the U.S. Food and Drug Administration. In this role, Eric authored the first IT Strategic Plan for FDA and was responsible for modernizing and enhancing the IT capabilities as well as the in silico scientific capabilities at FDA.

Eric has served on the editorial board of Cancer Today magazine, on the editorial board and as the Associate Editor for Novel Communications for the DIA flagship publication, the Journal of and Therapeutic Innovation and Regulatory Science. Eric has also served on several the Advisory Committees for the American Society of Clinical Oncology, the SAB of NuMedii, the leadership team of Precision for Medicine, as the Chairman of the Survivor Advisory Board at the Cancer Institute of New Jersey and as the Chief Information Officer of the King Hussein Institute for Biotechnology and Cancer in Amman, Jordan. Eric has also worked extensively with the LiveStrong Foundation, the Kidney Cancer Association, and the Scientist Survivor program of the American Association for Cancer Research. Eric has also served as the first CTO for OneMind4Research and as a reviewer for Faster Cures.

Prior to FDA, Eric was Senior Vice President of R&D Information Technology at Johnson & Johnson Pharmaceuticals R&D and was a member of the Corporate Office of Science and Technology. During his thirteen years at J&J, Eric also held the posts of Vice President R&D Informatics, Vice President and Chief Information Officer, Director of Research Information Technology as well as assistant Director and Director of Drug Discovery Research. Prior to J&J, Eric was the Group leader of Scientific Computing at ArQule Inc. and he began his professional career with the Army Corps of Engineers.

Eric has a PhD in chemical and biochemical engineering from Drexel University and also holds B.S.Che and M.S. degrees in chemical engineering.
Anthony Rowe headshot

Anthony Rowe, Ph.D.
Business Technology Leader – Immunology TA, JPC, JHML, ImmunoScience COE
Janssen Research and Development IT

* Complimentary one-on-one meetings with select industry analysts and consultants will be scheduled during the two days of the Summit.

** Advisory Board Members


Matt Hannon headshot Delegate Registrations
Matt Hannon
CBI Events
[email protected]

Debra Chipman headshot Speaker Invites & Submissions
Event Partner Opportunities

Debra Chipman
Corey Lane Partners
[email protected]

Elizabeth Cutler headshot Sponsor & Exhibitor Opportunities
Elizabeth Cutler
Corey Lane Partners
[email protected]